JASPER THERAPEUTICS, INC. Operating Cash Flow
JASPER THERAPEUTICS, INC. (JSPR) reported Operating Cash Flow of -$21.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- JASPER THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.92M.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$14.55M.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$21.87M.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$17.00M.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$77.16M.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$62.60M.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$52.07M.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$45.86M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 5 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$21.47M 10-Q · filed 2026-08-14 | -$43.33M derived: sum of 3 quarters · filed 2026-08-14 | -$60.33M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2026-03-31 | -$14.55M 10-Q · filed 2026-05-14 | -$36.41M derived: sum of 2 quarters · filed 2026-05-14 | -$53.41M derived: sum of 3 quarters · filed 2026-05-14 | -$68.87M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-12-31 | -$21.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$38.87M derived: sum of 2 quarters · filed 2026-03-30 | -$54.32M derived: sum of 3 quarters · filed 2026-08-14 | -$77.16M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | -$17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$32.45M derived: sum of 2 quarters · filed 2026-08-14 | -$55.29M 10-Q · filed 2025-11-10 | -$76.43M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-06-30 | -$15.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$38.30M 10-Q · filed 2026-08-14 | -$59.43M derived: sum of 3 quarters · filed 2026-08-14 | -$73.48M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-03-31 | -$22.84M 10-Q · filed 2026-05-14 | -$43.98M derived: sum of 2 quarters · filed 2026-05-14 | -$58.03M derived: sum of 3 quarters · filed 2026-05-14 | -$69.71M derived: sum of 4 quarters · filed 2026-05-14 | |||||
| 2024-12-31 | -$21.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$35.19M derived: sum of 2 quarters · filed 2026-03-30 | -$46.87M derived: sum of 3 quarters · filed 2026-03-30 | -$62.60M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | -$14.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$25.73M derived: sum of 2 quarters · filed 2025-11-10 | -$41.47M 10-Q · filed 2025-11-10 | -$57.95M derived: sum of 4 quarters · filed 2025-11-10 | |||||
| 2024-06-30 | -$11.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$27.42M 10-Q · filed 2025-08-13 | -$43.90M derived: sum of 3 quarters · filed 2025-08-13 | -$55.88M derived: sum of 4 quarters · filed 2025-08-13 | |||||
| 2024-03-31 | -$15.74M 10-Q · filed 2025-05-12 | -$32.22M derived: sum of 2 quarters · filed 2025-05-12 | -$44.20M derived: sum of 3 quarters · filed 2025-05-12 | -$57.47M derived: sum of 4 quarters · filed 2025-05-12 | |||||
| 2023-12-31 | -$16.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$28.46M derived: sum of 2 quarters · filed 2025-02-28 | -$41.73M derived: sum of 3 quarters · filed 2025-02-28 | -$52.07M 10-K · filed 2025-02-28 | |||||
| 2023-09-30 | -$11.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$25.25M derived: sum of 2 quarters · filed 2024-11-07 | -$35.59M 10-Q · filed 2024-11-07 | -$48.23M derived: sum of 4 quarters · filed 2024-11-07 | |||||
| 2023-06-30 | -$13.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$23.61M 10-Q · filed 2024-08-13 | -$36.25M derived: sum of 3 quarters · filed 2024-08-13 | -$45.90M derived: sum of 4 quarters · filed 2024-08-13 | |||||
| 2023-03-31 | -$10.34M 10-Q · filed 2024-05-14 | -$22.98M derived: sum of 2 quarters · filed 2024-05-14 | -$32.62M derived: sum of 3 quarters · filed 2024-05-14 | -$41.98M derived: sum of 4 quarters · filed 2024-05-14 | |||||
| 2022-12-31 | -$12.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$22.29M derived: sum of 2 quarters · filed 2024-03-05 | -$31.64M derived: sum of 3 quarters · filed 2024-03-05 | -$45.86M 10-K · filed 2024-03-05 | |||||
| 2022-09-30 | -$9.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$19.00M derived: sum of 2 quarters · filed 2023-11-09 | -$33.21M 10-Q · filed 2023-11-09 | -$47.80M derived: sum of 4 quarters · filed 2023-11-09 | |||||
| 2022-06-30 | -$9.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$23.57M 10-Q · filed 2023-08-11 | -$38.15M derived: sum of 3 quarters · filed 2023-08-11 | -$45.26M derived: sum of 4 quarters · filed 2023-08-11 | |||||
| 2022-03-31 | -$14.21M 10-Q · filed 2023-05-12 | -$28.80M derived: sum of 2 quarters · filed 2023-05-12 | -$35.91M derived: sum of 3 quarters · filed 2023-05-12 | -$41.70M derived: sum of 4 quarters · filed 2023-05-12 | |||||
| 2021-12-31 | -$14.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$21.69M derived: sum of 2 quarters · filed 2023-03-08 | -$27.48M derived: sum of 3 quarters · filed 2023-03-08 | -$33.68M 10-K · filed 2023-03-08 | |||||
| 2021-09-30 | -$7.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$12.90M derived: sum of 2 quarters · filed 2022-11-10 | -$19.09M 10-Q · filed 2022-11-10 | -$24.49M derived: sum of 4 quarters · filed 2022-11-10 | |||||
| 2021-06-30 | -$5.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$11.99M 10-Q · filed 2022-08-12 | -$678.63K 10-Q · filed 2021-08-16 | -$17.38M derived: sum of 3 quarters · filed 2022-08-12 | -$29.85M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | -$6.20M 10-Q · filed 2022-05-12 | -$317.75K 10-Q · filed 2021-05-24 | -$11.59M derived: sum of 2 quarters · filed 2022-05-12 | -$24.06M derived: sum of 3 quarters · filed 2022-05-12 | -$24.23M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$5.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$17.86M derived: sum of 2 quarters · filed 2022-03-18 | -$18.03M derived: sum of 3 quarters · filed 2022-03-18 | -$18.27M 10-K · filed 2022-03-18 | -$640.98K 10-K · filed 2021-03-30 | ||||
| 2020-09-30 | -$12.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$12.64M derived: sum of 2 quarters · filed 2021-11-12 | -$12.87M 10-Q · filed 2021-11-12 | -$635.62K 10-Q · filed 2020-11-10 | |||||
| 2020-06-30 | -$173.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$406.72K 10-Q · filed 2021-08-16 | |||||||
| 2020-03-31 | -$232.87K 10-Q · filed 2021-05-24 | ||||||||
| 2019-12-31 | -$367.47K 10-K/A · filed 2021-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |